Allspring Global Investments Holdings LLC Acquires 8,979 Shares of Natera, Inc. $NTRA

Allspring Global Investments Holdings LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 2.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 463,477 shares of the medical research company’s stock after purchasing an additional 8,979 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.33% of Natera worth $94,183,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Reflection Asset Management acquired a new stake in Natera in the fourth quarter worth $29,000. Palladiem LLC acquired a new position in shares of Natera during the fourth quarter worth approximately $31,000. Bank of Jackson Hole Trust lifted its holdings in shares of Natera by 103.8% in the 4th quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock worth $37,000 after purchasing an additional 83 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Natera by 132.9% in the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock worth $35,000 after purchasing an additional 97 shares in the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new stake in Natera in the 4th quarter valued at $39,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Price Performance

NASDAQ:NTRA opened at $271.39 on Friday. The company has a market capitalization of $38.87 billion, a price-to-earnings ratio of -166.50 and a beta of 1.51. The business has a 50 day moving average of $233.97 and a 200 day moving average of $220.41. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04.

Insider Buying and Selling at Natera

In related news, Director Herm Rosenman sold 16,530 shares of Natera stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $250.00, for a total value of $4,132,500.00. Following the sale, the director owned 4,250 shares in the company, valued at $1,062,500. The trade was a 79.55% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the completion of the transaction, the director owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This trade represents a 64.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 178,872 shares of company stock worth $39,627,696 over the last three months. 5.05% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of analyst reports. UBS Group set a $260.00 price target on Natera in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Guggenheim upped their target price on shares of Natera from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Canaccord Genuity Group increased their target price on shares of Natera from $285.00 to $330.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wells Fargo & Company increased their price objective on shares of Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a research note on Friday, May 8th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Natera has an average rating of “Moderate Buy” and a consensus price target of $267.83.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.